Hart-Scott-Rodino Waiting Period Expires for Shire's Acquisition of ViroPharma

Hart-Scott-Rodino Waiting Period Expires for Shire's Acquisition of ViroPharma

PR Newswire

DUBLIN, Ireland, December 11, 2013

DUBLIN, Ireland, December 11, 2013 /PRNewswire/ --

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) relating to its
previously announced tender offer by a wholly owned subsidiary of Shire for
all outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM) expired at
11:59 p.m., Eastern U.S. time, on December 10, 2013. The expiration of the
HSR waiting period satisfies one of the conditions to the tender offer. The
tender offer remains subject to certain other conditions set forth in the
offer to purchase, including the termination of review or approval of the
transaction by the United Kingdom Office of Fair Trading and the satisfaction
of the minimum tender condition. The tender offer is scheduled to expire at
6:00 p.m., Eastern U.S. time, on Thursday, December 26, 2013, unless the
tender offer is extended.


Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal,
Internal Medicine and Regenerative Medicine and we are developing treatments
for symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas.



This announcement is for informational purposes only and does not constitute
an offer to purchase or a solicitation of an offer to sell ViroPharma common
stock. The offer to buy ViroPharma common stock is being made pursuant to a
tender offer statement (including the offer to purchase, letter of transmittal
and other related tender offer materials) filed by Shire Pharmaceutical
Holdings Ireland Limited (SPHIL) and a subsidiary of SPHIL with the U.S.
Securities and Exchange Commission (SEC) on November 25, 2013. In addition,
on November 25, 2013, ViroPharma filed with the SEC a
solicitation/recommendation statement on Schedule 14D-9 with respect to the
tender offer. Investors and security holders are urged to read both the
tender offer statement and the solicitation/recommendation statement as they
contain important information, including the terms and conditions of the
tender offer, that should be read carefully before any decision is made with
respect to the tender offer. Investors and security holders may obtain a free
copy of these materials and other documents filed by SPHIL and ViroPharma with
the SEC at the website maintained by the SEC at http://www.sec.gov/. The
tender offer statement and related materials, and the
solicitation/recommendation statement, may also be obtained for free by
contacting the information agent for the offer, MacKenzie Partners, Inc., at
(212) 929-5500 or toll-free at (800) 322-2885.

Copies of these materials and any documentation relating to the tender offer
are not being, and must not be, directly or indirectly, mailed or otherwise
forwarded, distributed or sent in, into or from any jurisdiction where to do
so would be unlawful.


Statements included in this announcement that are not historical facts are
forward-looking statements. Forward-looking statements involve a number of
risks and uncertainties and are subject to change at any time. In the event
such risks or uncertainties materialize, Shire's results could be materially
adversely affected. The risks and uncertainties include, but are not limited
to, that:

  oShire's proposed acquisition of ViroPharma may not be consummated due to
    the occurrence of an event, change or other circumstances that gives rise
    to the termination of the merger agreement;
  oa governmental or regulatory approval required for the proposed
    acquisition of ViroPharma may not obtained, or may be obtained subject to
    conditions that are not anticipated, or another condition to the closing
    of the proposed acquisition may not be satisfied;
  oViroPharma may be unable to retain and hire key personnel and/or maintain
    its relationships with customers, suppliers and other business partners
    pending the consummation of the proposed acquisition by Shire, or
    ViroPharma's business may be disrupted by the proposed acquisition,
    including increased costs and diversion of management time and resources;
  odifficulties in integrating ViroPharma into Shire may lead to the combined
    company not being able to realize the expected operating efficiencies,
    cost savings, revenue enhancements, synergies or other benefits at the
    time anticipated or at all;

and other risks and uncertainties detailed from time to time in Shire's or
ViroPharma's filings with the U.S. Securities and Exchange Commission,
including their respective most recent Annual Reports on Form 10-K.

For further information please contact:

    Investor Relations
    Eric Rojas                    erojas@shire.com     +1-781-482-0999
    Sarah Elton-Farr              seltonfarr@shire.com +44-1256-894157
    Jessica Mann                  jmann@shire.com      +44-1256-894-280
    Gwen Fisher                   gfisher@shire.com    +1-484-595-9836

SOURCE Shire plc
Press spacebar to pause and continue. Press esc to stop.